451 Studies Now Enrolling
EVERGREEN: A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years and Older
A Study to Determine Efficacy (how well it works) of a Respiratory Syncytial Virus (RSV) Vaccine
| Sponsor: | Janssen |
| Enrolling: | Male and Female Patients |
| Study Length: | 19 Months |
| Clinic Visits: | 4 |
| IRB Number: | AAAU0247 |
| U.S. Govt. ID: | NCT04908683 |
| Contact: | Darien Thomas: 646-565-8633 / hpcresearch@cumc.columbia.edu |
Additional Study Information:
RSV is an important cause of serious respiratory infections in older adults. In the US, severe RSV infections lead to about 177,000 hospitalizations and 10,000-14,000 deaths per year in adults aged 65 years and older. Infections typically occur in the winter months during RSV season. This study will assess the safety and effectiveness of a vaccine to prevent RSV lung infections in individuals aged 65 and older. If you are age 65 years or older, you may be eligible to participate. Not sure if you are eligible? Take the first step and request to be contacted by our study team. We'll follow up by asking you to complete a brief electronic pre-screen questionnaire to find out if you meet basic study criteria. If you meet basic criteria, we'll invite you to our research site to review the study for which you may be eligible and possibly draw blood to find out if you meet additional medical criteria.
This study is closed
Do You Qualify?
| Are you at least 65 years old? | Yes | No |
| Are you able to use smartphones, tablets, or computers? | Yes | No |
| Have you had cancer within the past 5 years? | Yes | No |
| Have you had major surgery in the past 4 weeks or plan to in the next 6 months? | Yes | No |
| Have you received an RSV vaccine in a previous RSV vaccine study? | Yes | No |